15,145 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Purchased by Jump Financial LLC

Jump Financial LLC acquired a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 15,145 shares of the biopharmaceutical company's stock, valued at approximately $3,564,000.

Several other hedge funds have also recently bought and sold shares of the business. Larson Financial Group LLC raised its stake in shares of Alnylam Pharmaceuticals by 187.2% during the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 73 shares in the last quarter. R Squared Ltd purchased a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $33,000. OFI Invest Asset Management purchased a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $35,000. Versant Capital Management Inc raised its stake in shares of Alnylam Pharmaceuticals by 77.6% during the 4th quarter. Versant Capital Management Inc now owns 190 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 83 shares in the last quarter. Finally, IFP Advisors Inc raised its stake in shares of Alnylam Pharmaceuticals by 24.2% during the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock worth $57,000 after purchasing an additional 47 shares in the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ALNY. StockNews.com raised Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Tuesday. William Blair reissued an "outperform" rating on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. Morgan Stanley lowered their price objective on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating on the stock in a report on Friday, April 11th. Chardan Capital reissued a "buy" rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. Finally, Scotiabank raised their target price on Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a "sector outperform" rating in a report on Monday, March 31st. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-two have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $315.58.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock traded up $5.18 on Wednesday, hitting $241.93. The company's stock had a trading volume of 203,303 shares, compared to its average volume of 860,519. The firm has a market cap of $31.47 billion, a P/E ratio of -111.49 and a beta of 0.30. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The company has a fifty day moving average price of $247.91 and a 200-day moving average price of $256.50. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Activity

In other news, CMO Pushkal Garg sold 52,592 shares of the business's stock in a transaction on Monday, January 27th. The shares were sold at an average price of $285.00, for a total value of $14,988,720.00. Following the sale, the chief marketing officer now owns 11,989 shares in the company, valued at approximately $3,416,865. The trade was a 81.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Phillip A. Sharp sold 11,250 shares of the business's stock in a transaction on Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total transaction of $3,093,750.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 71,234 shares of company stock worth $19,958,097. Corporate insiders own 1.20% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.